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Abstract
‘‘Day-7’’ myeloid DCs are commonly used in the clinic. However, there is a strong need to develop DCs faster that have the
same potent immunostimulatory capacity as ‘‘Day-7’’ myeloid DCs and at the same time minimizing time, labor and cost
of DC preparations. Although ‘‘2 days’’ DCs can elicit peptide-specific responses, they have not been demonstrated to
engulf, process and present complex whole tumor lysates, which could be more convenient and personalized source of
tumor antigens than defined peptides. In this preclinical study, we evaluated the T-cell stimulatory capacity of Day-2, Day-
4, and Day-7 cultured monocyte-derived DCs loaded with SKOV3 cell whole lysate prepared by freeze-thaw or by UVB-
irradiation followed by freeze-thaw, and matured with lipopolysaccharide (LPS) and interferon (IFN)-gamma. DCs were
evaluated for antigen uptake, and following maturation with LPS and IFN-gamma, DCs were assessed for expression of
CD80, CD40, CD86, ICAM-1 and CCR7, production of IL-12p70 and IP-10, and induction of tumor-specific T-cell responses.
Day-4 and Day-7 DCs exhibited similar phagocytic abilities, which were superior to Day-2 DCs. Mature Day-7 DCs
expressed the highest CD40 and ICAM-1, but mature Day-4 DCs produced the most IL-12p70 and IP-10. Importantly, Day-4
and Day-7 DCs derived from ovarian cancer patients stimulated equally strongly tumor-specific T-cell responses. This is the
first study demonstrating the highly immunogenic and strong T-cell stimulatory properties of Day-4 myeloid DCs, and
provided important preclinical data for rapid development of potent whole tumor lysate-loaded DC vaccines that are
applicable to many tumor types.
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Introduction
Dendritic cells (DCs) are the most potent antigen-presenting
cells in the human immune system. Due to their unique ability to
prime and stimulate both CD8
+ and CD4
+ T cells, DCs loaded
with whole tumor lysate have been investigated in several clinical
trials for their ability to induce therapeutic anti-tumor T cell
responses [1,2,3,4,5,6,7,8]. Beneficial anti-tumor responses have
been observed in some patients, illustrating the potential of this
approach. DCs can be classified into different subsets depending
on their lineage and receptor expression pattern. Their distinct
biology can be exploited for different therapeutic strategies. The
most widely used DCs for clinical trials are the myeloid DCs that
are differentiated from peripheral blood monocytes in the presence
of recombinant granulocyte-macrophage colony stimulating factor
(GM-CSF) and interleukin 4 (IL-4). In most trials, 7 days are used
to generate fully-differentiated ‘‘classic’’ DCs [9,10,11]. These
DCs exhibit high phagocytic capability. Upon maturation with an
appropriate stimulus, Day-7 DCs upregulate surface markers such
as CD80, CD86, CD40, and migration markers such as CCR7,
and can efficiently prime naive T cells [12,13,14].
To generate DC-based vaccines for rapid clinical trial use,
shorter DC differentiation protocols have been investigated.
Czerniecki and colleagues established a ‘‘rapid DC’’ protocol in
which monocytes were exposed for 2 days to recombinant GM-
CSF and IL-4, pulsed with an immunodominant HER-2/neu
peptide, and subsequently matured with lipopolysaccharide (LPS)
and interferon (IFN)-c before vaccination of patients with ductal
carcinoma in situ of the breast [15]. Such 2-day ‘‘rapid DCs’’
exhibit high surface expression of CD80, CD86, CD40, HLA-DR,
MHC Class I, and CCR7. They also produced high levels of IL-
12p70, which could be boosted further by stimulation with CD40
ligand. In addition, 2-day ‘‘rapid DCs’’ induced objective clinical
responses in some patients. Dauer et al produced DCs under a
similar 48-hour ‘‘FastDC’’ protocol in which the monocytes
acquired immature DC characteristics by two days of culture,
downregulated CD14, increased dextran uptake, and responded to
the inflammatory chemokine macrophage inflammatory protein-
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mature monocyte-derived DCs generated by a standard 7-day
protocol, and were found to be equally potent in priming
autologous naive T cells using tetanus toxoid as a model antigen.
Therefore, these fast ‘‘2-day DCs’’ offer a very attractive choice for
loading with synthetic immunodominant peptides. However, it is
currently unknown whether the antigen processing machinery of
these fast ‘‘2-day DCs’’ is sufficiently developed to efficiently
process and cross-present relevant tumor antigens from complex
whole tumor lysates.
The use of whole tumor lysates offers distinct advantages in
tumor vaccine preparation. First, all patients are eligible for DC-
whole tumor lysate therapy as patients are not selected based on
their HLA-A2 status. Second, whole tumor lysate provides a rich
array of tumor-associated antigens for both CD4
+ and CD8
+ T
cells. This is important as the parallel presentation of antigens to
both T cell types helps generating stronger primary immune
responses, and could prevent the emergence of tumor escape. The
presence of CD4
+ T cell help also promotes long-term CD8
+ T cell
memory [19,20,21]. In addition, DCs pulsed with whole tumor
lysate have shown enhanced efficacy in cancer patients over DCs
loaded with defined tumor-associated peptides or proteins, based
on meta-analytical data [22]. Tumor cells can be prepared in
numerous ways for DC-based immunotherapy [23]. Ultraviolet B
(UVB) irradiation and repeat freeze-thaw cycles are the two most
common methods for inducing tumor cell death.
In this study, we sought to evaluate DCs cultured for different
lengths of time (i.e. 2 days, 4 days or 7 days) for their abilities to: 1)
phagocytose UVB-irradiated tumor cell lysate or freeze-thawed
whole tumor cell lysate, 2) produce IL-12p70 and IP-10 after
maturation with LPS and IFN-c, and 3) stimulate tumor-specific
IFN-c responses in an autologous setting using DCs and T cells
derived from donors or patients with epithelial ovarian carcinoma
(EOC). This is the first study demonstrating that Day-4 myeloid
DCs are highly immunogenic and highly capable of priming
strong tumor-specific T cells in cancer patients and normal healthy
donors. Thus, this study provides important preclinical data for
the rapid development of potent whole tumor lysate loaded DC
vaccines that are applicable to many tumor types.
Materials and Methods
Ethics statement
All healthy donors and ovarian cancer patients are confirmed to
have given written informed consent to a tissue and blood
procurement study allowing ex vivo experimentation, which is
approved by the University of Pennsylvania’s Office of Regulatory
Affairs, Institutional Review Board (IRB).
Generation of dendritic cells
Fresh monocytes from normal healthy HLA-A2
+ and HLA-A2
2
donors, who had given written informed consent to the University
of Pennsylvania’s Office of Regulatory Affairs, Institutional
Review Board (IRB)-approved tissue procurement study, were
obtained from the University of Pennsylvania Human Immunol-
ogy Core Facility and prepared using the RosetteSepH Human
Monocyte Enrichment Cocktail kit by negative selection according
to the manufacturer’s protocol (STEMCELL Technologies Inc.,
Vancouver, Canada). Purified monocytes were resuspended at
5610
6 cells/ml in heat-inactivated fetal bovine serum (FBS)
[Invitrogen, Carlsbad, CA, USA] containing 10% DMSO and
frozen until required. Frozen elutriated monocytes were obtained
from ovarian cancer patients who had given written consent to this
IRB-approved protocol. Prior to donating monocytes for this
study, these patients had undergone debulking surgery, followed
by multiple rounds of chemotherapy. Frozen monocytes from
healthy volunteers or ovarian cancer patients were rapidly thawed
at 37uC, washed twice with DPBS (Cellgro, Manassas, VA, USA)
and resuspended at 1610
6 cells/ml in serum-free AIM-V media
supplemented with 2 mM L-glutamine, 100 units/ml penicillin,
and 100 mg/ml streptomycin (i.e. complete AIM-V media)
[clinical grade AIM-V from Invitrogen; all others from Cellgro].
Monocytes were cultured in the presence of 250 IU/ml recom-
binant human GM-CSF and 125 IU/ml IL-4 [both from
PeproTech, Rocky Hill, NJ, USA] for 2 days, 4 days, or 7 days
at 37uC, 5% CO2 to generate Day-2, Day-4 and Day-7 DCs,
respectively. At the end of the culture period, DCs were gently
harvested, and the surface expression of CD11c, CD14, HLA-DR,
and CD1c on DCs was determined. The DC purity was found to
be .98%.
CD3
+ T cells
Whole T cell populations from normal healthy HLA-A2
+
donors were obtained from the University of Pennsylvania Human
Immunology Core Facility, where the T cells were prepared using
the RosetteSepH Human T cell Enrichment Cocktail kit
(STEMCELL Technologies Inc) by negative selection according
to the manufacturer’s protocol and found to be .98% pure.
Ovarian cancer patients’ peripheral blood leukocytes
Frozen elutriated peripheral blood leukocytes (PBLs) were
obtained from ovarian cancer patients who had given written
consent to this IRB-approved protocol. Prior to donating PBLs for
this study, patients had undergone debulking surgery and multiple
rounds of chemotherapy.
Preparation of UVB-irradiated lysate and freeze-thawed
lysate of SKOV3
SKOV3 ovarian carcinoma cells were cultured in DMEM
media supplemented with 10% heat-inactivated FBS, 2 mM L-
glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin
(FBS from Invitrogen; all others from Cellgro). The cell line was
routinely tested for Mycoplasma and found to be negative. To
prepare UVB-irradiated and freeze-thaw SKOV3 lysates, 90%
confluent SKOV3 cell cultures were harvested, washed twice with
DPBS, and resuspended at 1610
6 cells/ml in complete AIM-V
media. For UVB-irradiation, SKOV3 cells were plated in 10 cm
Petri dishes (BD Falcon, San Jose, CA, USA) and subjected to a
302 nm UVB-irradiation (Spectroline, Westbury, NY, USA) for
10 min to induce apoptosis. Then cells were incubated overnight
at 37C, 5% CO2, and harvested on the following day for 6 cycles
of freeze-thaw treatment (freezing with dry ice for 20 min and
thawing at room temperature) before use. For freeze-thaw lysate
preparation, SKOV3 cells were transferred to 15 ml tubes (BD
Falcon) and subjected to 6 cycles of freeze-thaw treatment (as
above) before use.
Dendritic cell phenotyping
Day-2, Day-4, or Day-7 DCs were cocultured with UVB-
irradiated or freeze-thawed SKOV3 lysate at a cell ratio of 1:1 for
16 h at 37uC, 5% CO2. Then, 60 EU/ml of LPS (Escherchia coli;
Sigma, St. Louis, MO, USA) and 2000 IU/ml of IFN-c
(PeproTech) were added to the DC-tumor cocultures for a further
16 h to stimulate DC maturation. Unpulsed Day-2, Day-4, and
Day-7 DCs were cultured with or without LPS and IFN-c and
used as mature DCs (mDCs) and immature DCs (iDCs),
respectively. After 16 h, the cocultures were harvested and blocked
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heat-inactivated FBS). DCs in cocultures were identified by
staining with APC-conjugated anti-HLA-DR, PE-conjugated
anti-CD11c, PE-Cy7-conjugated anti-CD14, and one of the
FITC-conjugated monoclonal antibodies for DC maturation
markers (i.e. CD80, CD86, or CD40), or DC adhesion (ICAM-
1) or DC migration (CCR7) for 30 min on ice [all antibodies from
BD Pharmingen, San Jose, CA, USA]. For DC-LAMP expression,
DCs were stained with FITC-conjugated anti-HLA-DR, PE-
conjugated anti-CD1c, and PE-Cy7-conjugated anti-CD14, and
then subjected to fix-permeabilization (eBioscience, San Diego,
CA, USA) for 30 min at 4uC followed by intracellular staining
with APC-conjugated anti-DC LAMP, and finally two washes with
staining buffer. Flow cytometry was performed on a BD Canto
(Becton Dickinson, Franklin Lakes, NJ, USA) and data were
analyzed with Pro CellQuest software. Gated HLA-DR
+ CD11c
+
cells were selected for analysis of CD80, CD86, CD40, ICAM-1,
CCR7, or DC-LAMP. It was found that .98% of the cells were
HLA-DR
+ CD11c
+.
Uptake of UVB-irradiated and freeze-thawed lysates of
SKOV3 by dendritic cells
To prepare PKH26-labeled SKOV3 UVB-irradiated or freeze-
thaw lysates, tumor cells were first labeled with PKH26 membrane
dye (Sigma) according to the manufacturers’ protocol and used for
lysate preparations as described above. To determine uptake of
tumor lysate by Day 2, Day 4, or Day 7 DCs, labeled UVB-
irradiated or freeze-thaw SKOV3 lysates were cocultured with
DCs at a cell ratio of 1:1 for 4 h or 24 h at 37uC, 5% CO2.
Parallel control cultures were set up for 4 h or 24 h at 4uCt o
evaluate the passive transfer of dye or labeled tumor fragments to
DCs. After incubation, cocultures were harvested and DCs
identified by staining with APC-conjugated anti-HLA-DR for
30 min on ice. Cells were washed twice with staining buffer and
analyzed by flow cytometry as above. HLA-DR
+ cells were
selected for analysis for PKH26 positivity. DCs that had taken up
PKH26-labeled SKOV3 lysates were HLA-DR
+ PKH26
+.
ELISA
To evaluate production of IL-12p70 and IP-10 from lysate-
pulsed mature Day-2, Day-4, or Day-7 DCs, DCs were cocultured
with UVB-irradiated or freeze-thaw SKOV3 lysates at a cell ratio
of 1:1 for 16 h and matured with LPS and IFN-c for another 12 to
30 h to stimulate DC maturation. Coculture supernatants were
then collected by centrifugation for assessment. Unpulsed Day-2,
Day-4, or Day-7 DCs were cultured with or without LPS and IFN-
c (mature and immature DCs, respectively, as controls). Briefly,
NUNC MaxiSorp
TM 96-well ELISA plates (Fisher Scientific,
Rochester, NY, USA) were coated with capture IL-12p70
(BioLegend, San Diego, CA, USA) or IP-10 antibody (final
concentration of 1.5 ng/ml; BD Pharmingen) for 2 h at 37uC, 5%
CO2. Plates were then washed 4 times, and appropriately diluted
supernatants were incubated overnight at 4uC. Biotinylated
detection antibodies for IL-12p70 (BioLegend) or IP-10 (1.5 ng/
ml; BD Pharmingen) were added for 1 h incubation at room
temperature. Then plates were washed 5 times, and incubated
with alkaline phosphatase-conjugated streptavidin for 30 min, and
washed again prior to addition of TBM substrate solution.
Reactions were stopped by adding equal volumes of 1 N sulfuric
acid, and read using an ELISA plate reader (BioTek). A similar
protocol (BioLegend) was used to evaluate IFN-c production from
autologous T cells after 2 weeks of stimulation with lysate-pulsed
DCs.
Autologous T cell priming
For analysis of samples from normal healthy HLA-A2
+ donors,
Day-2, Day-4, or Day-7 DCs were cocultured with UVB-
irradiated or freeze-thaw SKOV3 lysates at a cell ratio of 1:1 for
16 h, then matured with LPS and IFN-c for 16 h, as above. Then
2610
6 DCs were harvested, washed twice with DPBS, and
cocultured with 2610
7 autologous CD3
+ T cells in complete AIM-
V supplemented with 5% human AB serum (Valley Biomedical
Inc., Winchester, VA, USA). IL-2 (50 IU/ml) and IL-7 (20 ng/ml)
(both from PeproTech) were added on days 3, 5, and 7 of
coculture. After 1 week, viable CD3
+ T cells were harvested,
washed twice with DPBS, and cocultured at 10 T cells to 1 DC
ratio for another week. Fresh IL-2 and IL-7 were added on days 3,
5 and 7 of the second week of coculture. To determine non-
antigen-specific T cell responses, cocultures of unpulsed Day-2,
Day-4, or Day-7 DCs and CD3
+ T cells were set up in parallel. At
the end of the second week culture, T cells were harvested,
washed, and plated in 96-well round bottom plates with fixed
SKOV3 expressing HLA-A2 (i.e. HLA-A2
+ SKOV3) cells.
SKOV3 tumor cells were fixed for 1 min with 0.05% glutaralde-
hyde (Sigma) and washed twice with DPBS before use. T2 cells
(HLA-A2
+ human T-B lymphoblast hybrids) were pulsed with
10 mg/ml HER-2/neu369–377 or HER-2/neu689–697 peptides (all
peptides $95% purity as determined by reverse-phase high
performance liquid chromatography; AnaSpec Inc, CA, USA) or
media (i.e. T cells alone) for 20 h at 37uC, 5% CO2. Then
supernatants were harvested and IFN-c production was assessed
by ELISA. For ovarian cancer patient sample analysis, Day-2,
Day-4, or Day-7 DCs were generated from autologous elutriated
monocytes and cocultured with UVB-irradiated or freeze-thaw
SKOV3 lysates at a cell ratio of 1:1 for 16 h, and matured with
LPS and IFN-c for 16 h, as described above. Then DCs were
harvested and cocultured with the patient’s autologous PBLs for a
total of 2 weeks, using the same procedures described above for
healthy volunteer autologous DC-T cell cocultures. At the end of
the second week culture, the patients’ T cells were harvested,
washed, and evaluated in IFN-c ELISPOT assay.
IFN-c ELISPOT
IFN-c ELISPOT was performed according to the manufactur-
er’s recommendations. Briefly, Multi-Screen
TM-Immobilon
TM-P
Filtration Plate (Millipore, Bedford, USA) were activated for
30 sec with sterile 70% ethanol (100 ml/well), then washed 56
with sterile distilled water (200 ml/well). Wells were coated with
anti-human IFN-c capture antibody (1-D1K clone; Mabtech, Inc.,
Mariemont, OH, USA) at 15 mg/ml in DPBS (100 ml/well)
overnight at 4uC. Then plates were washed five times with DPBS
and blocked with AIM-V media containing 10% human AB
serum for 1 h at 37uC, 5% CO2. Following that, media was
removed and T responder cells were seeded in the wells at 1610
5
cells/well. Cryopreserved autologous DCs that had been previ-
ously loaded with freeze-thaw SKOV3 lysate (i.e. FTL), and
matured with LPS and IFN-c for 16 h, were rapidly thawed,
washed, and fixed for 30 seconds with 0.05% glutaraldehyde
before coculturing with T responder cells at a 10 T cells to 1 DC
ratio. As specificity controls, T responder cells were cocultured
with unloaded mature DCs, or in the presence of media only.
HLA-A2
+ patient T responder cells were also tested for their
ability to secrete IFN-c in the presence of fixed HLA-A2
+ SKOV3
cells, T2 cells loaded with 10 mg/ml of HER-2/neu369–377 or
HER-2/neu689–697 peptides, or unpulsed T2 cells as background
control. The ELISPOT plate was incubated for 40 h at 37uC, 5%
CO2. After incubation, cells were removed by washing five times
with DPBS. The presence of IFN-c produced by antigen-specific
Day-4 DCs Prime Potent Tumor-Specific Response
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mouse anti-human IFN-c (2 h at room temperature), 5 washes
with DPBS, alkaline phosphatase-conjugated streptavidin (1 h at
room temperature), five further washes with DPBS, and substrates
for streptavidin. The number of spots corresponding to the IFN-c
producing cells was counted with an automatic plate reader
(Autoimmune Diagnostica GmbH, Strassberg, Germany), and the
results were expressed as IFN-c spots per 10
6 T cells.
Statistical methods
Measurements taken for Day-2, Day-4, and Day-7 DCs were
summarized by means and standard errors. For figure 1, statistical
significance was assessed using Student’s unpaired t test. The
comparisons among groups for % DC uptake of tumor cells in
figure 2, and the ratios of mature DC (mDC), UVB-lysate loaded
DC (UVB-DC) and FTL-loaded DC (FTL-DC) to immature DC
(iDC), and mean fluorescence intensity (MFI) of mDCs in figure 3,
were performed on natural log transformed data using ANOVA.
For those comparisons found to be statistically significant by
ANOVA, Tukey post hoc testing was used to conduct pairwise
comparisons. Measurements in figure 4 were summarized by
means and standard errors. In figure 5, IFN-c measurements were
compared amongst groups by the nonparametric Kruskal-Wallis
test due to the small group sizes and non-normality of the data,
and pairwise comparisons were performed by Wilcoxon rank sum
testing. In figure 6, statistical significance was assessed using
Student’s paired t test. A significance level of 0.05 or less was
considered statistically significant. Analyses were performed in
SPSS v19 (SPSS Inc, Chicago, IL).
Results
Phenotype of Day-2, Day-4 and Day-7 immature dendritic
cells
As monocytes differentiate into immature dendritic cells (iDCs)
in the presence of recombinant GM-CSF and IL-4, they
upregulate CD11c, lose CD14 surface expression and develop
distinct dendritic appearance. To evaluate iDCs for CD11c,
CD14, HLA-DR, CD68, and CD33 expression and morphology,
elutriated monocytes were cultured in serum-free AIM-V media in
the presence of GM-CSF (250 IU/ml) and IL-4 (125 IU/ml) for 2
days, 4 days or 7 days to induce differentiation into iDCs. It was
Figure 1. Day-4 and Day-7 DCs, but not Day-2 DCs acquired phenotypic features of differentiated DCs. Elutriated monocytes derived
from normal healthy donors were cultured for 2, 4, or 7 days in serum-free AIM-V media supplemented with recombinant GM-CSF and IL-4, and
analyzed by flow cytometry at the end of the culture period. (A) Representative histograms from 1 out of 6 donors were shown here. The MFIs
indicated in the histograms were derived by subtracting the MFI of the test sample from the isotype control. Day-2 DCs expressed slightly higher
CD14, CD68, and CD33 markers than Day-4 and Day-7 DCs, while Day-4 DCs were similar to Day-7 DCs in immunophenotype. (B) The average MFIs of
the different DC maturation markers of 6 normal healthy donors were shown here. ** P value=,0.001; highly significant when comparing the MFI of
Day-4 or Day-7 DCs to the MFI of Day-2 DCs by Student’s unpaired t test.
doi:10.1371/journal.pone.0028732.g001
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expressed CD11c. However, Day-2 iDCs expressed approximately
20- and 10-fold lower CD11c compared to Day-4 iDCs
(P=,0.0001) and Day-7 iDCs (P=,0.0001) [Figs. 1A, B]. All
three DC preparations had substantially lower CD14 expression
compared to starting monocytes and Day-6 macrophages that
were developed only with macrophage colony-stimulating factor
(Figs. 1A, B). The lowest CD14 expression was found on Day-4
and Day-7 iDCs (P=,0.0001), while Day-2 iDCs comprised a
population with higher CD14 expression. All three DC prepara-
tions expressed intermediate levels of HLA-DR, as expected of
iDCs. However, Day-4 iDCs expressed the highest level of HLA-
DR (P values=,0.0002; compared to Day 2 and Day 7 iDCs). All
iDCs exhibited low CD33 and CD68, which are markers for
monocytes and macrophages, respectively (Figs. 1A, B). Day-2
iDCs were smaller in size as compared to Day-4 and Day-7 iDCs
by flow cytometry analysis (data not shown). Thus, Day-4 iDCs
were phenotypically similar to Day-7 iDCs, while Day-2 iDCs
were not fully differentiated.
Phagocytic ability of Day 2, Day 4 and Day 7 immature
dendritic cells
To prepare tumor cell lysates, SKOV3 tumor cells were labeled
with PKH26 and treated with 1) UVB-irradiation, followed by 6
Figure 2. Day-4 DCs, but not Day-2 DCs, were as phagocytic as Day-7 DCs in actively engulfing ovarian tumor lysate. (A) Day-2, Day-4,
and Day-7 DCs were cocultured with UVB lysate (UVBL) or freeze-thaw lysate (FTL) of PKH26-labeled SKOV3 cells at 37uC for 4 h or 24 h to determine
active phagocytosis of tumor lysates. Representative dot plot results from 1 out of 6 donors are shown here. DCs that had engulfed PKH26-labeled
tumor lysate appear as the HLA-DR
+ PKH26
+ double-positive population, and are expressed as the percentage of the total number of HLA-DR
+ DCs as
indicated in the upper-right quadrant of the dot plots. (B) DCs were cocultured with lysate at 4uC for 4 h or 24 h as controls to determine passive
transfer of the PKH26 dye to DCs. Representative dot plot results from 1 out of 6 donors are shown here. HLA-DR
+ PKH26
+ double-positive DCs are
expressed as the percentage of the total number of HLA-DR
+ DCs as indicated in the upper-right quadrant of the dot plots. (C) Summary results of the
percentages of Day-2, Day-4, and Day-7 DCs that have engulfed PKH26-labeled UVBL or FTL after 4 h or 24 h, at both 4uC and 37uC. Data displayed
are the means 6 standard errors of six independent experiments. There are no significant differences among Day-2, Day-4 and Day-7 DCs for the
precentage of DCs taking up UVBL (ANOVA P value=0.13) or FTL (ANOVA P value=0.59) at 4 h. However, there is a significant difference for % of DCs
taking up UVBL at 24 h (ANOVA P value=0.02). By post hoc paired testing, % of Day-2 DCs taking up UVBL was significantly lower than either Day-7 or
Day-4 DCs (*P values=0.05 and 0.02, respectively). Highly significant differences were also observed for the uptake of FTL at 24 h (ANOVA**P
value,0.001). The % of Day-2 DCs taking up FTL was significantly lower than either Day-7 or Day-4 DCs (**P values,0.001 for each). The differences
between Day-4 and Day-7 DCs were insignificant for uptake of both UVBL (P value=0.90) and FTL (P value=0.92).
doi:10.1371/journal.pone.0028732.g002
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(UVBL), or 2) 6 cycles of freeze-thaw alone to generate freeze-
thawed whole tumor cell lysate (FTL). To assess the phagocytic
ability of immature Day-2, Day-4 and Day-7 DCs, UVBL or FTL
lysate preparations were then cocultured with the different DC
preparations. DCs were identified by the expression of HLA-DR,
and DCs that had phagocytosed tumor lysate were identified as
HLA-DR
+ PKH26
+ double-positive. There was a rapid uptake of
UVBL by Day-2, Day-4, and Day-7 iDCs at 37uC after 4 h of
incubation (Fig. 2A). Day-4 and Day-7 iDCs showed similarly
strong phagocytic capabilities at 24 h at 37uC, whereas Day-2
iDCs took up less tumor lysate under the same conditions (Fig. 2A).
Phagocytosis of FTL occurred to a slightly lesser extent than
UVBL after 24 h at 37uC. (Fig. 2A). Uptake of tumor lysate by the
iDCs was confirmed to be an active process, as passive transfer of
tumor fragments onto DC surfaces at 4uC was minimal (Fig. 2B).
Summarizing the results from 6 normal healthy donor DC samples
in Fig. 2C, Day-4 and Day-7 iDCs showed similarly high uptake
($75%) of UVBL and FTL after 24 h at 37uC[ P=0.90 and
p=0.92, respectively], and Day-2 iDCs showed a significantly
lower uptake ability at 24 h at 37uC (approximately 50–60%;
P=0.05 for UVBL uptake and ,0.0001 for FTL uptake when
compared to Day-4 and Day-7 iDCs). Thus, Day-4 iDCs were as
capable as Day-7 iDCs in the phagocytosis of whole tumor cell
lysates.
Maturation of tumor lysate-pulsed Day 2, Day 4, and Day
7 dendritic cells
One of the potential concerns of preparing lysate-loaded DCs is
that tumor lysates could suppress the ability of DCs to undergo
Figure 3. Day-2, Day-4 and Day-7 DCs pulsed with UVBL or FTL mature normally following LPS and IFN-c stimulation. Following
lysate loading, DCs were stimulated with LPS (60 EU/ml) and IFN-c (2000 IU/ml) for 16 h. DCs were identified by HLA-DR, CD11c and one of the
markers shown. Unpulsed immature DCs (iDCs) and mature (mDCs) were set up in parallel and harvested at the same time as the other tumor lysate-
loaded mature DCs for analysis. (A–C) Upregulation of maturation markers CD80, CD40, CD86, ICAM-1, and CCR7 is observed on mature Day-2, Day-4
and Day-7 DCs. The open histograms represent the isotype control, while shaded histograms represent the DC markers. The solid line marks the MFI
of the different markers on iDCs for each condition. Representative histogram results from 1 out of 6 donors are shown here. (D) Fold-increase in
expression levels of maturation and adhesion markers on mDCs, UVBL-loaded DCs (UVBL-DC) or FTL-loaded DCs (FTL-DC) over iDC was determined
by expressing the MFIs as a ratio of the DCs to unpulsed iDCs. Highly significant differences were detected in CD86 (**P value=0.002), ICAM-1 (**P
value=,0.001), and CCR7 (**P value=0.002, ,0.001 and 0.008, respectively; ANOVA followed by post-hoc testing) on unpulsed matured Day-4 DCs
compared to unpulsed matured Day-7 DCs. Similar highly significant differences were detected in CD86 and CCR7 (**P value=0.001, and 0.01,
respectively; ANOVA followed by post-hoc testing) on Day-4 UVBL-DCs compared to Day-7 UVBL-DCs. CD86 and ICAM-1 (**P value=0.001, and 0.01,
respectively; ANOVA followed by post-hoc testing) were also significantly different on Day-4 FTL-DCs compared to Day-7 FTL-DCs. (E) The overall
immunophenotypes of DCs loaded with UVBL or FTL were similar to unpulsed mature DCs, however Day-4 DCs loaded with UVBL consistently
expressed slightly higher levels of most markers including CD80, CD86 and CCR7 relative to any other lysate-DC preparations.
doi:10.1371/journal.pone.0028732.g003
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iDCs that had phagocytosed UVBL or FTL were able to respond
normally to LPS and IFN-c stimulation, DCs were incubated with
the relevant lysate for 16 h and stimulated with 60 EU/ml LPS
and 2000 IU/ml IFN-c for an additional 16 h. Lysate-loaded
Day-2 and Day-4 iDCs upregulated maturation and migration
markers upon stimulation with LPS and IFN-c when compared to
their non-stimulated, unpulsed counterparts (Figs. 3A, B). Non-
stimulated, unpulsed immature Day-7 DCs showed upregulation
of markers such as CD80, CD40 and CD86 (Fig. 3C, top panel) in
serum-free culture conditions, in agreement with other groups
[24,25,26]. Nevertheless, Day-7 lysate-loaded iDCs were able to
further upregulate CD40 and ICAM-1 expression upon stimula-
tion with LPS and IFN-c. Summary results from 6 different donors
are shown in Fig. 3D; expression changes are shown as fold-
upregulation of mean fluorescence intensity (MFI) following
exposure to LPS and IFN-c over baseline (non-stimulated and
unpulsed) iDCs at the same time point. Numerous markers were
significantly upregulated over baseline under various conditions
(Fig. 3D). Day-4 DCs, whether unpulsed and matured, or pulsed
with UVBL or FTL and matured, showed higher relative
upregulation of most markers (except CD80 when loaded with
FTL) in comparison to Day-7 DCs. Day-7 DCs that were pulsed
with lysate and stimulated with LPS and IFN-c showed no further
upregulation of CD80, CD86 or CCR7 over baseline Day-7 DCs.
To evaluate the final immunophenotype of mature Day-2, Day-
4 and Day-7 DCs pulsed with either UVBL or FTL, we compared
them to mature unpulsed DCs. Overall, the immunophenotypes of
mature DCs pulsed with FTL or UVBL were similar to unpulsed
mature DCs, with some exceptions (Fig. 3E). Day-2, Day-4 and
Day-7 UVBL-pulsed mature DCs showed lower CD40 than
mature unpulsed DCs. This was also the case with Day-2 and Day-
4 FTL-pulsed mature DCs, but CD40 was upregulated in Day-7
FTL-pulsed mature DCs. Interestingly, Day-2 and Day-4 DCs
pulsed with UVBL had overall a very similar immunophenotype
after maturation with LPS and IFN-c. Upon analysis of all the
surface markers, it was found that Day-4 DCs pulsed with UVBL
consistently expressed slightly higher levels of most markers
including CD80, CD86 and CCR7 relative to any other lysate-
DC preparation.
IL-12p70 and IP-10 production by lysate-pulsed dendritic
cells
IL-12 produced by DCs is critical for complete priming of naive
T cells. To determine the IL-12p70 production profile of Day-2,
Figure 4. Day-4 DCs produce the highest levels of IL-12p70 and IP-10. Day-2, Day-4, and Day-7 DCs were first pulsed with either UVBL or FTL
for 16 h, and then stimulated with LPS (60 EU/ml) and IFN-c (2000 IU/ml) to determine (A) IL-12p70 and, (B) IP-10 production. Supernatants from the
DC-tumor lysate cocultures were collected and evaluated by ELISA as described in Materials and Methods. The results are from 4 different normal
healthy donors and are expressed as mean (pg/ml) 6 standard errors.
doi:10.1371/journal.pone.0028732.g004
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FTL for 16 h, and then stimulated with LPS and IFN-c for 12 to
30 h.IL-12p70 proteinwas quantifiedin culture supernatants at 12,
18, 24, or 30 h. Day-2 UVBL or FTL-pulsed DCs that were
stimulated with LPS and IFN-c produced the least amount of IL-
12p70 at 30 h (Fig. 4A). Day-4 DCs pulsed with either UVBL or
FTL produced higher amount of IL-12p70 than did lysate-pulsed
Day-2 or Day-7 DCs after LPS and IFN-c stimulation. IL-12p70
production increased steadily through 30 h (Fig. 4A). As expected,
unpulsed and unstimulated Day-2, Day-4 and Day-7 DCs (no LPS
or IFN-c) did not produce IL-12p70 (data not shown). Importantly,
Day-2, Day-4 and Day-7 DCs that had phagocytosed tumor
fragments did not exhibit impaired IL-12p70 production after LPS
and IFN-c stimulation, for they displayed similar profiles as their
unpulsed mature Day-4 or Day-7 counterparts [Fig. 4A; DC (no
antigen)]. Interestingly, lysate-pulsed mature Day-2 DCs produced
higher IL-12p70 compared to their unpulsed mature counterparts.
Interferon-inducible protein (IP)-10 (also known as CXCL10)
chemokine is produced by many cell types including DCs. Its
expression is induced by IFN-c and TNF-a, and it is used as an
indication of IFN-c activity [27]. It was noted that IP-10
production by UVBL-pulsed and FTL-pulsed DCs started early,
with high levels already being produced at 12 h. UVBL-pulsed
mature Day-2, Day-4, and Day-7 DCs produced similarly high
amount of IP-10 at 30 h (Fig. 4B). For FTL-pulsed DCs, Day-4
and Day-7 DCs produced similar IP-10, whereas Day-2 DCs
produced less IP-10 at 30 h. Mature unpulsed DCs followed a
similar pattern of IP-10 production as FTL-lysate pulsed DCs,
with Day-4 and Day-7 DCs producing more IP-10 than Day-2
DCs (Fig. 4B). In summary, Day-4 UVBL-pulsed mature DCs
produced the highest amount of IL-12p70 and had comparable
expression of IP-10 to all other lysate-DC preparations.
Priming of tumor-reactive T cells by autologous tumor
lysate-pulsed matured dendritic cells
To assess the ability of Day-2, Day-4, and Day-7 DCs to prime
human donor T cells reactive against tumor antigens, DCs
developed from the peripheral blood mononuclear cells (PBMCs)
of normal healthy HLA-A2
+ donor as above were either left
unpulsed or pulsed with UVBL or FTL of SKOV3 cells, then
matured with LPS and IFN-c, and used to stimulate in vitro
autologous CD3
+ T cells for two consecutive weeks. Then, viable
autologous T cells were harvested, and evaluated in ELISA for
their recall ability to recognize ovarian antigens and produce IFN-
c in response to live HLA-A2
+ SKOV3 cells. Because SKOV3
cells express HER-2/neu [28,29,30], we also tested the ability of
DCs to prime donor T cells against HLA-A2 restricted peptides
HER-2/neu369–377 and HER-2/neu689–697 pulsed on T2 cells
(which are HLA-A2
+). Day-4 and Day-7 UVBL-pulsed DCs
elicited autologous T cells that secreted high IFN-c against HLA-
A2
+ SKOV3 and T2 cells pulsed with HER-2/neu369–377 or
HER-2/neu689–697 peptides (Fig. 5). In contrast, minimal IFN-c
production was observed when T cells were exposed to unpulsed
T2 cells alone or to media (i.e. T cells only; no antigen), indicating
that IFN-c production was ovarian tumor-specific. Day-4 DCs
were as potent as Day-7 DCs in priming tumor-reactive T cells to
secret high levels of IFN-c in response to live HLA-A2
+ SKOV3,
and to T2 cells pulsed with HER-2/neu369–377 or HER-2/
neu689–697 peptides. On the other hand, Day-2 DCs stimulated
poor tumor-specific IFN-c production from the T cells (Fig. 5).
Importantly, UVBL-pulsed DCs were more potent than FTL-
pulsed DCs in eliciting autologous T cells that were reactive to live
HLA-A2
+ SKOV3 and T2 cells pulsed with HER-2/neu peptides.
Thus, UVBL-pulsed DCs were more effective in priming tumor-
reactive autologous T cells than FTL-pulsed DCs, and Day-4 DCs
were as efficient as Day-7 DCs.
Next, we compared the stimulatory capacity of Day-2, Day-4,
and Day-7 DCs derived from elutriated monocytes of three
ovarian cancer patients to elicit tumor-specific T cell responses.
DCs generated from the patients were pulsed with SKOV3-
derived UVBL or FTL and evaluated for their ability to stimulate
antigen-specific T cell responses. After two weeks of stimulation
with lysate-pulsed DCs or unpulsed DCs, bulk autologous T cells
were harvested for IFN-c ELISPOT. T cells were examined for
Figure 5. Day-4 DCs derived from normal healthy HLA-A2
+ donors pulsed with UVBL or FTL and matured with LPS and IFN-c,
stimulate potent and specific autologous ovarian tumor-reactive T cell responses in vitro. Day-2, Day-4, and Day-7 DCs were pulsed with
lysate for 16 h and matured with LPS (60 EU/ml) and IFN-c (2000 IU/ml) for a further 16 h before being used for priming T cells. After 2 weeks of in
vitro stimulation, T cells were harvested and evaluated for their ability to recognize ovarian tumor-associated antigens. The IFN-c responses of T cells
previously stimulated with UVBL-pulsed DCs (grey bars), FTL-pulsed DCs (black bars) or unpulsed mature [no antigen] DCs (white bars) are shown
here. Data were obtained from 3 different individuals and displayed as the means 6 standard errors. Day-2 DCs result in no significant T cell priming,
while Day-4 and Day-7 DCs elicit T cells that are able to produce significant amounts of IFN-c in response to live HLA-A2
+ SKOV3 cells or to HLA-A2
+
T2 cells pulsed with HER-2/neu369–377 (H369) or HER-2/neu689–697 (H689). Using Kruskal-Wallis test by post-hoc paired testing, Day-2 DCs are
significantly lower than either Day-7 or Day-4 DCs (*P values=0.05 for all tests), and no differences are detected when comparing Day-4 and Day-7
DCs (P values $ 0.28). FTL-pulsed DCs perform better than UVBL-pulsed DCs in priming ovarian-specific IFN-c T cell responses.
doi:10.1371/journal.pone.0028732.g005
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with SKOV3 FTL, or unpulsed DCs. For patient 3 who was HLA-
A2 positive, T cells were also tested against T2 cells pulsed with
HER-2/neu369 or HER-2/neu689 peptides, and live HLA-A2
+
SKOV3. T cells alone and T cells stimulated with anti-CD3
antibody (data not shown) were used as control.
T cells from patients 1 and 2 (both were HLA-A2
2) that had
received primary stimulation with FTL-pulsed Day-4 or Day-7
DCs responded to FTL-pulsed DCs in the IFN-c ELISPOT assay.
It was observed that Day-7 FTL-pulsed DCs stimulated a slightly
higher number of IFN-c secreting T cells (average of 900 IFN-c
spots) than did Day-4 FTL-pulsed DCs (average of 750 IFN-c
spots) [Fig. 6A]. UVBL-pulsed Day-4 or Day-7 DCs stimulated a
higher number of IFN-c secreting T cells compared to FTL-pulsed
Day-4 or Day-7 DCs. The antigen-specificity of these responses
was demonstrated by the low number of IFN-c secreting T cells
(average of 250 IFN-c spots) when they were cultured alone, or in
the presence of Day-4 or Day-7 unpulsed DCs. Day-2 DCs elicited
no tumor-reactive IFN-c producing T cells. Similar results were
observed in the T cells of patient 3 who was HLA-A2
+, where a
greater number of T cells that had been previously stimulated with
Day-4 or Day-7 UVBL-pulsed DCs produced IFN-c upon
recognition of ovarian antigens as compared to T cells that were
previously stimulated with Day-4 or Day-7 FTL-pulsed DCs
(Fig. 6B). Day-2 DCs from patient 3 were also unable to elicit anti-
tumor responses in the T cells. In addition, a greater number of T
cells that were previously stimulated with Day-4 UVBL-pulsed
DCs could specifically recognize HER-2/neu369 and HER-2/
neu689 peptides on T2 cells and DCs loaded with SKOV3 FTL
compared to T cell that were previously stimulated with Day-7
UVBL-pulsed DCs. These T cells also recognized ovarian HLA-
A2
+ SKOV3. Importantly, very few IFN-c spots were detected in
T cells alone culture or when T cells were cultured with unpulsed
DCs in the ELISPOT assay. The IFN-c ELSIPOT results showed
that Day-4 DCs were as potent as Day-7 DCs in eliciting anti-
tumor responses in autologous T cells, while Day-2 DCs were
incapable of eliciting tumor-reactive IFN-c T cell responses
(Figs. 6A, B).
Figure 6. Day-4 DCs derived from EOC patients, stimulated potent and specific autologous ovarian tumor-reactive T cell responses
in vitro. Patients’ T cells were cocultured with autologous Day-2, Day-4 or Day-7 mature DCs previously pulsed with SKOV3 UVBL or FTL for 2 weeks
and then interrogated for reactivity against tumor antigens. The IFN-c responses of patients’ T cells previously stimulated with UVBL-pulsed DCs
(closed squares or black bars), FTL-pulsed DCs (closed circles or white bars) or unpulsed mature DCs (closed triangles or grey bars) are shown here, (A)
For patients 1 and 2 who were HLA-A2
2, the T cells were tested in the presence of autologous DCs pulsed with SKOV3 FTL, autologous unpulsed DCs,
or media (T cells only). (B) For patient 3, who was HLA-A2
+, the T cells were also tested against live HLA-A2
+ SKOV3 cells, HLA-A2
+ T2 pulsed with HER-
2/neu 369 or 689 peptides, autologous DCs pulsed with HLA-A2
2 SKOV3 FTL, autologous unpulsed DCs, or media (T cells only). The results are the
means of the number of IFN-c spots per 10
6 T cells 6 standard error. The asterisks indicate those columns differing significantly (P value=0.001;
Student’s paired t test) from the media (i.e. T cells only) controls.
doi:10.1371/journal.pone.0028732.g006
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Human DCs can be differentiated from various cellular sources,
such as CD34
+ progenitor cells from bone marrow and cord blood
[31,32], or circulating monocytes from the PBMC population
[9,10,11]. As monocytes can easily be obtained in large numbers
from peripheral blood, they are currently the most popular
precursor cells for generating DCs. In the classic Day-7 DC
protocol, monocytes are cultured in the presence of recombinant
GM-CSF and IL-4 for a total of 7 days in order to fully
differentiate them into myeloid DCs. In our hands, Day-7
monocyte derived DCs markedly downregulated CD14 and
CD33 expression, and upregulated CD11c and HLA-DR
expression as compared to monocytes or macrophages, in
agreement with existing literature. Indeed, Day-7 MoDCs loaded
with tumor antigens have already been used successfully in the
clinic to elicit anti-tumor responses in cancer patients
[1,2,3,4,5,6,7,8].
To speed DC vaccine preparation, and to reduce costs and
labor requirements, shorter Day-2 DC preparation protocols have
been developed. These monocyte-derived ‘‘rapid DCs’’ are shown
to be similar in phenotype to Day-7 DCs in terms of expressing
high levels of CD86, HLA-DR, and CCR7 upon maturation.
These Day-2 DCs were also shown to be able to produce IL-12,
take up latex beads or dextran [16,17,18], and stimulate tetanus
toxoid (TT) [17] or anti-HER-2/neu [15] T cell responses when
loaded with TT or HER-2/neu peptides. In this study, we sought
to optimize the length of DC culture (i.e. 2, 4 or 7 days of culture)
for use with whole tumor cell lysate as source of antigens in the
clinic. Whole tumor lysates offer many distinct advantages over
defined peptides or proteins; for example, T cell responses can be
elicited against tumor-associated antigens without prior knowledge
of the specific antigens. It is important to note that increased
efficacy has been reported when whole tumor lysates were used as
a source of antigen in DC-based cancer immunotherapy [23].
Thus, whole tumor lysates are ideal sources of antigens for DCs to
prime anti-tumor responses. The use of whole tumor lysate
requires DCs to have fully functional antigen processing
machinery, to allow processing of complex tumor lysates into
peptides for presentation to T cells in association with appropriate
MHC molecules. However, it was unknown if Day-2 MoDCs
already acquired the necessary antigen processing and presenta-
tion machinery for processing whole tumor lysates, and for
priming anti-tumor T cells responses.
In order to develop a DC protocol compatible with clinical use,
we made the choice of culturing the monocyte-derived DCs in
clinial grade serum-free AIM-V media for several reasons: 1) AIM-
V media has been widely used for DC and T cell generation; 2) it
is approved for clinical use by the Food and Drug Administration
(FDA); and 3) it is manufactured under current Good Manufac-
turing Practices (GMP). Thus, in this regard, our cultures differ
from those published by the Dauer [17] and Czerniecki groups
([15], in that we did not use macrophage serum-free media
because it is used mainly for growing monocytes and macrophag-
es, and it is not available in therapeutic grade for clinical use.
Similarly, we did not use RPMI 1640 media, because although it is
widely used for immunological studies including the culturing of
DCs, it is only available in research grade not suited for clinical
use.
We demonstrated that DCs that were cultured in serum-free
AIM-V media in the presence of recombinant GM-CSF and IL-4
for 2 days retained many monocytic-like features, i.e. higher CD14
expression and smaller size compared to Day-7 DCs that were
cultured in the same media condition but for 7 days. Although
CD14 expression was downregulated after 2 days of DC culture,
approximately half of the Day-2 DCs still expressed high levels of
surface CD14. These Day-2 DCs also expressed lower levels of
CD80, CD86, CD40, ICAM-1 and CCR7 than Day-7 DCs after
stimulation with LPS and IFN-c. It is to be emphasized that
monocytes that have been activated with LPS and IFN-c also
upregulate CD86, HLA-DR, and CCR7 expression, and produce
high levels of IL-12 [33] in a fashion similar to DCs (data not
shown). Therefore, upregulation of these markers in the presence
of high levels of CD14 and/or CD33 should not be considered as
confirmation of attaining full DC differentiation and maturation.
Although Day-2 ‘rapid DCs’ have been demonstrated to be able to
stimulate antigen-specific response in breast cancer patients when
loaded with tumor-associated peptides [15], no antigen processing
is necessary under these circumstances, since the immunodomi-
nant peptides can bind directly to the MHC molecules that are
expressed on the DCs. Therefore, this could explain why loading
MHC Class I-restricted immunodominant peptides on high MHC
Class I expressing Day-2 ‘‘rapid DCs’’ can elicit strong peptide-
specific CD8
+ responses in the study conducted by Czerniecki and
colleagues.
By extending the monocyte-derived DC culture to 4 days in our
culture system, all DCs reduced their CD14 to a level that was
comparable to that of Day-7 DCs. This demonstrated that the 4
days of culture was sufficient to differentiate monocytes into DCs
that were similar to Day-7 DCs. By day 4, immature DCs had an
active phagocytic ability and were as capable as Day-7 iDCs to
take up whole tumor cell lysates. Day-4 iDCs were able to
upregulate maturation markers such as CD80, CD86, CD40 and
ICAM-1, and migration markers such as CCR7, upon LPS and
IFN-c stimulation. In addition, Day-4 iDCs had a higher capacity
to upregulate these markers compared to Day-7 iDCs (Fig. 3D).
Day-7 iDCs generated with our serum-free protocol exhibited a
more mature phenotype compared to Day-2 or Day-4 DCs prior
to stimulation with LPS and IFN-c, with higher CD80, CD86, and
HLA-DR expression. However, these Day-7 iDCs exhibited a
high phagocytic ability, which is a distinct feature of immature
DCs. Also, Day-7 iDCs that were not stimulated with LPS and
IFN-c did not produce IL-12p70 [data not shown], and they only
did so after full activation from LPS and IFN-c stimulation
[Fig. 4A]. It should be noted that we initially followed Czerniecki
group’s protocol [15] by stimulating DCs first with LPS for
6 hours before adding IFN-c for another 12 hours. However, we
could not detect any IL-12p70 production by this staggered
manner in our DC culture system (data not shown). When we
added both LPS and IFN-gamma simultaneously in the DC
cultures, we could consistently detect high levels of IL-12p70.
Therefore we chose to administer LPS and IFN-gamma at the
same time to mature DCs in this study.
IL-12 is an important cytokine produced by mature DCs upon
appropriate simulation, such as bacterial LPS. IL-12 is necessary
for skewing towards a Th1 response, which is essential for tumor
killing. IFN-c has a powerful effect in enhancing the ability of DCs
to produce IL-12, and IL-12 also enhances the production of IFN-
c, thus creating a positive reinforcement loop [34]. Thus, it was
predicted that simultaneous stimulation of DCs with LPS and
IFN-c would induce robust IL-12 production from DCs. IP-10 is a
highly inducible, primary response gene that belongs to the C-X-C
chemokine superfamily [27,35]. Its production is increased
following IFN-c stimulation. It has numerous biological actions,
including stimulation of monocytes and natural killer cells, T cell
migration, regulation of T cell and bone marrow progenitor
maturation, modulation of adhesion molecule expression, and
inhibition of angiogenesis [35].
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with either tumor lysate produced higher levels of IL-12p70 at
30 h than did Day-7 or Day-2 DCs. This indicated that Day-4
DCs were equally, if not more, sensitive to LPS and IFN-c than
were Day-2 and Day-7 DCs; their production of IL-12p70 was
greater than Day-7 DCs and their IP-10 secretion up to 30 h was
comparable to that of Day-7 DCs. In contrast, Day-2 DCs showed
the poorest IL-12p70 and IP-10 production, which highly
suggested that these DCs had not developed sufficiently to fully
respond to LPS and IFN-c stimulation. It has been demonstrated
that DCs that are further stimulated with CD40 ligand after LPS
and IFN-c treatment enhanced their IL-12p70 production [15]
and this approach could further enhance the immunogenicity of
the Day-4 DCs.
Day-4 lysate pulsed DCs were as potent as Day-7 DCs in
stimulating autologous T cells in both healthy donors as well as in
ovarian cancer patients; these T cells recognized live ovarian
tumor cell lines and ovarian tumor-associated antigens, and
produced IFN-c as a result. Although Day-4 DCs generally
expressed lower levels of maturation markers (i.e. CD80 and
CD40), and adhesion (ICAM-1) or migration molecules (CCR7)
after maturation than Day-7 DCs, this did not affect their ability to
stimulate potent ovarian-specific responses in the T cells derived
from healthy volunteers and ovarian cancer patients. It was
interesting to note that Day-4 or Day-7 DCs that were loaded with
UVBL were able to elicit stronger IFN-c ovarian tumor specific
responses compared to DCs loaded with FTL. Different whole
tumor cell lysate preparations could potentially impact the
immunogenicity of DC-whole tumor lysate vaccines. It could be
postulated that mixed apoptotic/necrotic tumor cell death induced
by UVB-irradiation, and not cell death via freeze-thawed cycles,
was able to release more potent danger signals (e.g. from the
release of heat-shock proteins, uric acid or High Mobile group
protein B1) for activating DCs. We are currently evaluating and
optimizing whole tumor lysate preparations for loading onto these
Day-4 myeloid DCs.
In summary, we developed a faster, Day-4 DC protocol using
GM-CSF, IL-4, and serum-free AIM-V media that is suitable for
clinical use. We showed specifically that Day-4 DCs generated
from this protocol are similar to ‘‘classic’’ Day-7 DCs in terms of
phenotype and phagocytic capability and have a higher capacity
than Day-7 DCs to produce IL-12p70 and IP-10 following LPS
and IFN-c stimulation. In addition, these Day-4 DCs are highly
immunogenic, and efficiently prime and stimulate strong ovarian
tumor-specific T cells derived from both healthy volunteers and
ovarian cancer patients. It should be noted that we did not directly
compare the Day-4 DCs generated with this protocol to the Day-2
‘‘rapid DCs’’ as reported by Dauer et al., or Czerniecki et al.
[15,17]. Due to some variations in our method reported here
relative to theirs (e.g. media and maturation stimuli for DCs), we
could not conclude that Day-4 DCs are universally superior to
Day-2 DCs in all culture systems and for all antigen types.
However, based on the results in this study, we conclude that Day-
4 DCs generated using GM-CSF, IL-4 and serum-free AIM-V
media and pulsed with whole tumor antigen are superior to Day-2
DCs generated in the same culture condition for priming strong
and specific tumor-specific T cell responses. This is the first study
demonstrating the strong T cell stimulatory capability of shorter
Day-4 DCs pulsed with whole tumor lysate. Given the overall
superior performance of whole-tumor lysate preparations over
molecularly defined antigens for cancer vaccines and the overall
superiority of DC-based vaccines [22], our results provide
important preclinical data for the rapid development of potent,
highly immunogenic DC-whole tumor lysate vaccines for treating
many tumor types.
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